<DOC>
	<DOCNO>NCT01225406</DOCNO>
	<brief_summary>This observational cohort study virologic immunologic outcome least 48 week third line antiretroviral therapy . Upto 150 child 8 Thai site enrol . Third line antiretroviral therapy study define antiretroviral ( ARV ) regimen patient failure intolerance first line NNRTI-based therapy second line PI-based therapy . Such regimen may contain new drug drug class darunavir , tipranavir , etravirine raltegravir The knowledge gain study help Thai government plan strategy provide third line ARV therapy child within national program .</brief_summary>
	<brief_title>Third Line Highly Active Antiretroviral Therapy ( HAART ) HIV-infected Children</brief_title>
	<detailed_description>The primary objective study assess virological efficacy , measure proportion child HIV RNA 400 50 copies/ml 48 week initiate third line ARV therapy . Third line ARV therapy define ARV regimen patient failure intolerance first line NNRTI-based therapy second line PI-based therapy . Such regimen may contain new drug drug class darunavir , tipranavir , etravirine raltegravir</detailed_description>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Children ( &lt; 18 year old ) HIV infection may enroll one follow criterion meet : 1 . Have resistance least one drug 3 class ( NRTI , NNRTI PI ) plasma HIV RNA &gt; 1000 copies/ml prior switch third line ARV therapy 2 . Have intolerance current NRTI , NNRTI PI treatment need receive darunavir , etravirine , tipranavir raltegravir 1 . Have hepatic impairment ALT â‰¥ 5 upper limit normal 2 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Third line ARV therapy</keyword>
	<keyword>HIV RNA</keyword>
	<keyword>Absolute CD4+ T cell count</keyword>
	<keyword>serious adverse event ( SAEs )</keyword>
	<keyword>Drug resistance</keyword>
</DOC>